Celularity Inc
NASDAQ:CELU

Watchlist Manager
Celularity Inc Logo
Celularity Inc
NASDAQ:CELU
Watchlist
Price: 2.96 USD -17.55% Market Closed
Market Cap: 70.9m USD

Operating Margin
Celularity Inc

-70.8%
Current
-96%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-70.8%
=
Operating Profit
-38.4m
/
Revenue
54.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Celularity Inc
NASDAQ:CELU
66.7m USD
-71%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
336.1B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
129.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Celularity Inc
Glance View

Market Cap
66.7m USD
Industry
Biotechnology

Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company is headquartered in New York City, New York and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).

CELU Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-70.8%
=
Operating Profit
-38.4m
/
Revenue
54.2m
What is the Operating Margin of Celularity Inc?

Based on Celularity Inc's most recent financial statements, the company has Operating Margin of -70.8%.

Back to Top